Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla.
Department of Dermatology, School of Medicine, University of Pittsburgh, PA.
J Manag Care Spec Pharm. 2022 Nov;28(11):1213-1218. doi: 10.18553/jmcp.2022.28.11.1213.
Early after the onset of the COVID-19 pandemic, concerns were raised that the use of psoriasis treatments, particularly biologic therapies because of their immunosuppressant effects, could be associated with a poor prognosis in the case of COVID-19 infection. To examine changes in adherence to systematic biologic therapies for psoriasis after the onset of the COVID-19 pandemic. Using IQVIA medical and pharmacy claims data from January 1, 2018, to October 31, 2020, we identified patients aged 18 years or older who had a diagnosis of plaque psoriasis in 2018 and who received systemic biologic therapies for psoriasis, including both provider-administered and pharmacy-dispensed therapies. We calculated the incidence of 14-day gaps without therapy per 1,000 study participants for each 30-day interval. We constructed interrupted time series analyses to test changes in the incidence of outcomes after the pandemic declaration. The sample included 15,890 study participants: 45.4% were female and 15.2% were aged 65 years or older. For patients using biologic therapies dispensed from the pharmacy, there was a 13.1% decrease in the incidence of 14-day gaps without biologic therapy immediately after pandemic declaration, from 92.4 gaps per 1,000 patients to 80.2 gaps per 1,000 patients, but this decrease was not statistically significant. However, for patients using provider-administered therapies, the incidence of 14-day gaps without biologic therapy increased by 55.1% after pandemic declaration, from 29.0 gaps per 1,000 patients to 44.9 gaps per 1,000 patients ( < 0.01). Following the onset of the COVID-19 pandemic, we found an increased incidence of gaps in biologic therapy for psoriasis among users of provider-administered treatments but not among users of pharmacy-dispensed therapies. Dr Hernandez reports personal fees from Bristol Myers Squibb and personal fees from Pfizer outside the submitted work. Dr Hernandez is funded by the National Heart, Lung and Blood Institute (grant K01HL142847). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The statements, findings, conclusions, views, and opinions expressed in this publication are based on data obtained under license from IQVIA as part of the IQVIA Institute's Human Data Science Research Collaborative.
在 COVID-19 大流行早期，人们担心使用银屑病治疗方法，特别是生物疗法，因为它们具有免疫抑制作用，可能与 COVID-19 感染的预后不良有关。为了研究 COVID-19 大流行后系统性生物疗法治疗银屑病的依从性变化。使用 IQVIA 医疗和药房索赔数据，从 2018 年 1 月 1 日至 2020 年 10 月 31 日，我们确定了 2018 年诊断为斑块状银屑病且接受过系统性生物疗法治疗银屑病的 18 岁及以上患者，包括提供者管理和药房配药的疗法。我们计算了每 1000 名研究参与者在每个 30 天间隔内无治疗的 14 天治疗间隔。我们构建了中断时间序列分析，以检验大流行宣布后结果发生率的变化。样本包括 15890 名研究参与者：45.4%为女性，15.2%为 65 岁及以上。对于从药房配药的生物疗法使用者，大流行宣布后无生物疗法治疗的 14 天间隔发生率下降了 13.1%，从每 1000 名患者 92.4 个间隙下降到每 1000 名患者 80.2 个间隙，但无统计学意义。然而，对于使用提供者管理的治疗方法的患者，大流行宣布后无生物疗法治疗的 14 天间隔发生率增加了 55.1%，从每 1000 名患者 29.0 个间隙增加到每 1000 名患者 44.9 个间隙（<0.01）。在 COVID-19 大流行开始后，我们发现使用提供者管理的治疗方法的银屑病生物疗法的中断发生率增加，但使用药房配药的治疗方法的中断发生率没有增加。Hernandez 博士报告了 Bristol Myers Squibb 的个人酬金和 Pfizer 的个人酬金，这些酬金均来自于提交工作之外。Hernandez 博士由美国国立心肺血液研究所（grant K01HL142847）资助。该资助者在研究的设计和实施、数据的收集、管理、分析和解释、手稿的准备、审查、批准或提交发表方面没有任何作用。本出版物中表达的陈述、发现、结论、观点和意见是基于从 IQVIA 获得的数据，这些数据是 IQVIA 研究所人类数据科学研究协作的一部分。
